Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of UBX1325 in DME or nAMD
NCT04537884Phase 1Completed
- Sponsor
- Unity Biotechnology
- Start
- Oct 2020
- Primary completion
- Jan 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of foselutoclax in diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD), sponsored by Unity Biotechnology. Primary endpoint: Ocular and systemic safety and tolerability evaluated by incidence of DLTs and TEAEs at 24 weeks. Started Oct 2020; status: completed.
02
Drugs
foselutoclax
03
Conditions
diabetic macular edema (DME)neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT04537884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04537884.